List of Zavzpret drug patents

Zavzpret is owned by Pfizer.

Zavzpret contains Zavegepant Hydrochloride.

Zavzpret has a total of 3 drug patents out of which 0 drug patents have expired.

Zavzpret was authorised for market use on 09 March, 2023.

Zavzpret is available in spray, metered;nasal dosage forms.

Zavzpret can be used as administration of zavegepant for acute treatment of migraine with or without aura.

Drug patent challenges can be filed against Zavzpret from 2027-03-10.

The generics of Zavzpret are possible to be released after 07 October, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7220862 PFIZER Calcitonin gene related peptide receptor antagonists
Jan, 2024

(7 months from now)

US8481546 PFIZER CGRP receptor antagonist
Oct, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7314883 PFIZER Anti-migraine treatments
Dec, 2023

(6 months from now)

Do you want to check out ZAVZPRET patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 9, 2028

Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient

NCE-1 date: 2027-03-10

Market Authorisation Date: 09 March, 2023

Treatment: Administration of zavegepant for acute treatment of migraine with or without aura


More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in